(Q36708358)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

A systematic review of the safety of topical therapies for atopic dermatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

Callen J

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Chamlin S

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Eichenfield LF

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Ellis C

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Girardi M

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Goldfarb M

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Hanifin J

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Lee P

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Margolis D

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Piacquadio D

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Peterson W

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Kaulback K

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Fennerty M

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Wintroub BU

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

language of work or name

English

0 references

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Dermatology

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

203-221

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17223859%20AND%20SRC:MED&resulttype=core&format=json

Atopic dermatitis and the atopic march

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Clinical practice. Atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Consensus statement on the safety profile of topical calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Further evidence of the safety of tar in the management of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Doxepin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Frequency of sensitization to antimicrobials in patients with atopic eczema compared with nonatopic individuals: analysis of multicentre surveillance data, 1995-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Intermittent topical corticosteroid/tacrolimus sequential therapy improves lichenification and chronic papules more efficiently than intermittent topical corticosteroid/emollient sequential therapy in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Pimecrolimus: a review of its use in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Highly increased urinary 1-hydroxypyrene excretion rate in patients with atopic dermatitis treated with topical coal tar.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Short‐term growth and bone turnover in children undergoing occlusive steroid (‘Wet‐Wrap’) dressings for treatment of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Anti-tumor-promoting action of FK506, a potent immunosuppressive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment and skin carcinogenesis in the DMBA/TPA model in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Cancer epidemiology in the last century and the next decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Primary cutaneous CD30+ large T-cell lymphoma in a patient with psoriasis treated with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Aplastic anaemia incidence in parts of the United Kingdom in 1985

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Aetiologic factors in lymphoid malignancies: a case-control epidemiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergic conditions and risk of hematological malignancies in adults: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Leukemia, lymphoma, and multiple myeloma following selected medical conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Incidence of cancer among patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Cancer mortality among US men and women with asthma and hay fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Is the risk of lung cancer reduced among eczema patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Cutaneous findings in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Atopic disease and childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Medically recorded allergies and the risk of childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Prior history of allergies and pancreatic cancer in the San Francisco Bay area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

History of allergies and autoimmune diseases and risk of brain tumors in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Validity of patient self-reported history of skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Childhood indicators of susceptibility to subsequent cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Lung cancer risk in a population-based cohort of patients hospitalized for asthma in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergy and the risk of selected digestive and laryngeal neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergy and risk of breast cancer among young women (United States)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Infectious diseases in the first year of life, perinatal characteristics and childhood acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Non-Hodgkin's lymphoma among asthmatics exposed to pesticides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Day care, childhood infections, and risk of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A meta-analysis of asthma and risk of lung cancer (United States).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A multicenter trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Acute and maintenance treatment of atopic dermatitis in children – two comparative studies with fluticasone propionate (0.05%) cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Modern topical glucocorticoids and anti-infectives for superinfected atopic eczema: do prednicarbate and didecyldimethylammoniumchloride form a rational combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Do urea and sodium chloride together increase the efficacy of moisturisers for atopic dermatitis Skin? A comparative, double-blind and randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A double-blind study comparing the effect of glycerin and urea on dry, eczematous skin in atopic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Short-term effects of topical fusidic acid or mupirocin on the prevalence of fusidic acid resistant (FusR) Staphylococcus aureus in atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Topical sodium cromoglycate in atopic dermatitis. A disappointing but informative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Efficacy and acceptability of a new topical skin lotion of sodium cromoglicate (Altoderm) in atopic dermatitis in children aged 2-12 years: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Topical vitamin B12--a new therapeutic approach in atopic dermatitis-evaluation of efficacy and tolerability in a randomized placebo-controlled multicentre clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Allergy and other selected diseases and risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X

Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07538.X